Drug Development

Anti-Cancer Drug Passes First Clinical Hurdle

Published in Cancer Weekly, June 27th, 2000

Australian pharmaceutical company, Novogen Limited (NVGN; NRT) announced the completion of the first stage of Phase I clinical evaluation of its anti-cancer drug, NV-06.

These initial trials were conducted at a major public hospital in Sydney, Australia, to provide data on blood level changes over time, and the tolerability of the drug in humans.

NV-06 was delivered as a single intravenous injection to a small number of cancer patients. Dr. Graham Kelly, Novogen, said the initial results are encouraging. "NV-06 behaved in the human blood stream just as predicted from pre-clinical studies," said Kelly. "The result marks an important milestone in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry